Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2005 2
2007 2
2008 2
2009 1
2011 3
2012 1
2013 2
2014 1
2016 1
2017 1
2018 1
2019 2
2020 1
2021 3
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean nadin haddad (7 results)?
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Neven P, Rugo HS, Tolaney SM, Iwata H, Toi M, Goetz MP, Kaufman PA, Lu Y, Haddad N, Hurt KC, Sledge GW Jr. Neven P, et al. Among authors: haddad n. Breast Cancer Res. 2021 Aug 23;23(1):87. doi: 10.1186/s13058-021-01463-2. Breast Cancer Res. 2021. PMID: 34425869 Free PMC article. Clinical Trial.
Varicocele: a dilemma in adolescent males.
Haddad NG, Houk CP, Lee PA. Haddad NG, et al. Pediatr Endocrinol Rev. 2014 Feb;11 Suppl 2:274-83. Pediatr Endocrinol Rev. 2014. PMID: 24683951 Review.
Turner syndrome (45x) with clitoromegaly.
Haddad NG, Vance GH, Eugster EA, Davis MM, Kaefer M. Haddad NG, et al. J Urol. 2003 Oct;170(4 Pt 1):1355-6. doi: 10.1097/01.ju.0000085983.81063.3f. J Urol. 2003. PMID: 14501769 No abstract available.
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2--Advanced Breast Cancer.
Neven P, Johnston SRD, Toi M, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Haddad N, Hurt KC, Llombart-Cussac A, Sledge GW. Neven P, et al. Among authors: haddad n. Clin Cancer Res. 2021 Nov 1;27(21):5801-5809. doi: 10.1158/1078-0432.CCR-20-4685. Epub 2021 Aug 10. Clin Cancer Res. 2021. PMID: 34376533
28 results